Arbormed

ArborMed is a biopharmaceutical company committed to the development and commercialization of therapeutics for diseases with high unmet medical needs and untapped market opportunities. With operations in South Korea and US, Arbormed utilizes resources efficiently to enable "Fast to Market" development of the pipeline and US market entry. Our Demand-Driven Development (D³) approach incorporates 3 strategic pillars to build a risk-balanced pipeline: Innovative new drug - starting from mid preclinical stage, develop best in class therapies with validated targets with a particular focus on rare diseases. Complex generics - commercialize complex generic products with limited competition in the US that have been developed by Korean companies.